Publication: Personal neoantigen cancer vaccines: The momentum builds
Open/View Files
Date
2014
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Landes Bioscience
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Fritsch, Edward F, Nir Hacohen, and Catherine J Wu. 2014. “Personal neoantigen cancer vaccines: The momentum builds.” Oncoimmunology 3 (1): e29311. doi:10.4161/onci.29311. http://dx.doi.org/10.4161/onci.29311.
Research Data
Abstract
Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient’s tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.
Description
Other Available Sources
Keywords
neoantigen, vaccine, personalized, central tolerance, T cells
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service